Difference between revisions of "Bleomycin (Blenoxane)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Category:Drug index" to "Category:Drugs")
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
Line 58: Line 58:
 
[[Category:Vascular sarcoma medications]]  
 
[[Category:Vascular sarcoma medications]]  
  
−
[[Category:Drugs FDA approved in 1973]]
+
[[Category:FDA approved in 1973]]
 
[[Category:WHO Essential Cancer Medicine]]
 
[[Category:WHO Essential Cancer Medicine]]

Revision as of 19:03, 30 July 2018

General information

Class/mechanism: Exact mechanism unknown, but suspected to inhibit DNA synthesis, with some evidence inhibition of RNA and protein synthesis. When administered intrapleurally for malignant pleural effusion, bleomycin acts as a sclerosing agent.[1]
Route: IV, IM, SC, intrapleural
Extravasation: irritant or neutral, depending on reference

  • 1 unit of bleomycin = 1 mg of bleomycin

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 7/31/1973: Initial FDA approval

Also known as

  • Brand names: Blenoxane, Bleo, Bleocin, Bleocip, Bleopar, Bleowel

References

  1. ↑ 1.0 1.1 Bleomycin (Blenoxane) package insert (locally hosted backup)
  2. ↑ Bleomycin (Blenoxane) patient drug information (Chemocare)
  3. ↑ Bleomycin (Blenoxane) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Bleomycin_(Blenoxane)&oldid=29209"